These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24597490)

  • 1. Prospects for MEK inhibitors for treating cancer.
    Martin-Liberal J; Lagares-Tena L; Larkin J
    Expert Opin Drug Saf; 2014 Apr; 13(4):483-95. PubMed ID: 24597490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
    Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trametinib (GSK1120212) in the treatment of melanoma.
    Salama AK; Kim KB
    Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of MEK inhibitors in the treatment of metastatic melanoma.
    Grimaldi AM; Simeone E; Ascierto PA
    Curr Opin Oncol; 2014 Mar; 26(2):196-203. PubMed ID: 24419498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.
    Tolcher AW; Bendell JC; Papadopoulos KP; Burris HA; Patnaik A; Jones SF; Rasco D; Cox DS; Durante M; Bellew KM; Park J; Le NT; Infante JR
    Ann Oncol; 2015 Jan; 26(1):58-64. PubMed ID: 25344362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trametinib.
    Zeiser R
    Recent Results Cancer Res; 2014; 201():241-8. PubMed ID: 24756797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trametinib-associated Hyponatremia in a Child With Low-grade Glioma is Not Seen Following Treatment With Alternative MEK Inhibitor.
    Lazow MA; Lawson SA; Salloum R; Hummel TR; Pillay Smiley N; DeWire-Schottmiller MD; Fouladi M; de Blank P
    J Pediatr Hematol Oncol; 2021 May; 43(4):e550-e553. PubMed ID: 32520842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK inhibition in BRAF-mutated melanoma.
    MacKenzie A; Boycott K
    N Engl J Med; 2012 Oct; 367(14):1364-5. PubMed ID: 23034029
    [No Abstract]   [Full Text] [Related]  

  • 9. MEK inhibition in BRAF-mutated melanoma.
    Ascierto PA
    N Engl J Med; 2012 Oct; 367(14):1364; author reply 1365. PubMed ID: 23034028
    [No Abstract]   [Full Text] [Related]  

  • 10. Promises from trametinib in RAF active tumors.
    Sausville EA
    N Engl J Med; 2012 Jul; 367(2):171-2. PubMed ID: 22663012
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.
    Seghers AC; Wilgenhof S; Lebbé C; Neyns B
    Melanoma Res; 2012 Dec; 22(6):466-72. PubMed ID: 22584957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers.
    Ho MY; Morris MJ; Pirhalla JL; Bauman JW; Pendry CB; Orford KW; Morrison RA; Cox DS
    Xenobiotica; 2014 Apr; 44(4):352-68. PubMed ID: 23971497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.
    Patnaik A; Tolcher A; Papadopoulos KP; Beeram M; Rasco D; Werner TL; Bauman JW; Scheuber A; Cox DS; Patel BR; Zhou Y; Hamid M; Schramek D; Sharma S
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):491-500. PubMed ID: 27392790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEK inhibitor-induced dusky erythema: characteristic drug hypersensitivity manifestation in 3 patients.
    Patel U; Cornelius L; Anadkat MJ
    JAMA Dermatol; 2015 Jan; 151(1):78-81. PubMed ID: 25426865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trametinib in the treatment of multiple malignancies harboring MEK1 mutations.
    Lian T; Li C; Wang H
    Cancer Treat Rev; 2019 Dec; 81():101907. PubMed ID: 31715422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel mitogen-activated protein kinase kinase inhibitors.
    Chapman MS; Miner JN
    Expert Opin Investig Drugs; 2011 Feb; 20(2):209-20. PubMed ID: 21235429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent tattoo reactions in a patient treated with BRAF and MEK inhibitors.
    Reinhard R; Gebhardt C; Schmieder A; Umansky V; Utikal J
    J Eur Acad Dermatol Venereol; 2017 Aug; 31(8):e375-e377. PubMed ID: 28222227
    [No Abstract]   [Full Text] [Related]  

  • 18. A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.
    Kumamoto T; Aoki Y; Sonoda T; Yamanishi M; Arakawa A; Sugiyama M; Shirakawa N; Ishimaru S; Saito Y; Maeshima A; Maeda M; Ogawa C
    Int J Hematol; 2019 Feb; 109(2):228-232. PubMed ID: 30361829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapsing pneumonitis due to two distinct inhibitors of the MAPK/ERK pathway: report of a case.
    Giraud V; Longvert C; Houlle-Crepin S; Danel C; Labrune S; Camus P; Saiag P; Chinet T
    BMC Cancer; 2015 Oct; 15():732. PubMed ID: 26481107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous Reactions in Children Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib for Neural Tumors.
    Boull C; Hook K; Moertel C; Maguiness S
    Pediatr Dermatol; 2017 Jan; 34(1):90-94. PubMed ID: 27981612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.